417 related articles for article (PubMed ID: 35563367)
1. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.
Hildebrandt J; Häfner N; Kritsch D; Görls H; Dürst M; Runnebaum IB; Weigand W
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563367
[TBL] [Abstract][Full Text] [Related]
2. Novel Nickel(II), Palladium(II), and Platinum(II) Complexes with
Hildebrandt J; Häfner N; Görls H; Barth MC; Dürst M; Runnebaum IB; Weigand W
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743112
[TBL] [Abstract][Full Text] [Related]
3. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
[TBL] [Abstract][Full Text] [Related]
4. Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
Büchel GE; Gavriluta A; Novak M; Meier SM; Jakupec MA; Cuzan O; Turta C; Tommasino JB; Jeanneau E; Novitchi G; Luneau D; Arion VB
Inorg Chem; 2013 Jun; 52(11):6273-85. PubMed ID: 23659478
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective anticancer activity of half-sandwich ruthenium and osmium complexes with modified curcuminoid ligands.
Pagliaricci N; Pettinari R; Marchetti F; Pettinari C; Cappellacci L; Tombesi A; Cuccioloni M; Hadiji M; Dyson PJ
Dalton Trans; 2022 Sep; 51(35):13311-13321. PubMed ID: 35983757
[TBL] [Abstract][Full Text] [Related]
6. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
[TBL] [Abstract][Full Text] [Related]
7. Varying the metal to ethacrynic acid ratio in ruthenium(ii)/osmium(ii)-p-cymene conjugates.
Păunescu E; Soudani M; Clavel CM; Dyson PJ
J Inorg Biochem; 2017 Oct; 175():198-207. PubMed ID: 28779652
[TBL] [Abstract][Full Text] [Related]
8. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapeutic Activities of New η
Ywaya DO; Ibrahim H; Friedrich HB; Bala MD; Soobramoney L; Daniels A; Singh M
Molecules; 2024 Feb; 29(5):. PubMed ID: 38474456
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes.
Marloye M; Inam H; Moore CJ; Debaille V; Pritchard JR; Gelbcke M; Meyer F; Dufrasne F; Berger G
J Biol Inorg Chem; 2021 Aug; 26(5):535-549. PubMed ID: 34173882
[TBL] [Abstract][Full Text] [Related]
11. Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes.
Sathiya Kamatchi T; Mohamed Subarkhan MK; Ramesh R; Wang H; Małecki JG
Dalton Trans; 2020 Aug; 49(32):11385-11395. PubMed ID: 32776042
[TBL] [Abstract][Full Text] [Related]
12. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
13. Metal complexes as DNA intercalators.
Liu HK; Sadler PJ
Acc Chem Res; 2011 May; 44(5):349-59. PubMed ID: 21446672
[TBL] [Abstract][Full Text] [Related]
14. Effect of
Mukherjee A; Acharya S; Purkait K; Chakraborty K; Bhattacharjee A; Mukherjee A
Inorg Chem; 2020 May; 59(9):6581-6594. PubMed ID: 32295347
[TBL] [Abstract][Full Text] [Related]
15. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
16. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
[TBL] [Abstract][Full Text] [Related]
17. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
18. Reactive Oxygen Species Production Is Responsible for Antineoplastic Activity of Osmium, Ruthenium, Iridium and Rhodium Half-Sandwich Type Complexes with Bidentate Glycosyl Heterocyclic Ligands in Various Cancer Cell Models.
Kacsir I; Sipos A; Bényei A; Janka E; Buglyó P; Somsák L; Bai P; Bokor É
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054999
[TBL] [Abstract][Full Text] [Related]
19. New glycoconjugation strategies for Ruthenium(II) arene complexes via phosphane ligands and assessment of their antiproliferative activity.
Iacopini D; Vančo J; Di Pietro S; Bordoni V; Zacchini S; Marchetti F; Dvořák Z; Malina T; Biancalana L; Trávníček Z; Di Bussolo V
Bioorg Chem; 2022 Sep; 126():105901. PubMed ID: 35671646
[TBL] [Abstract][Full Text] [Related]
20. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
